Safety, Tolerability and Abeta-specific Antibody Response of Repeated i.m. Injections of Adjuvanted CAD106 in Mild Alzheimer Patients

Clinical trial NCT01097096 · COMPLETED

Trial details

NCT number: NCT01097096
Sponsor: Novartis Pharmaceuticals
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Alzheimer's Disease

Start date: 2010-03-01
Primary completion: 2012-12-01
Enrollment: 177

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.